AtheroGenics Expands Discovery Research; Names James A. Sikorski,
Ph.D. as Director of Medicinal Chemistry
ATLANTA, March 12 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX - news), an emerging pharmaceutical
company focused on the discovery, development and commercialization of novel drugs to treat chronic inflammatory
diseases, today announced that James A. Sikorski, Ph.D. has joined the company as Director of Medicinal Chemistry.
Reporting to William A. Scott, Ph.D., Vice President of Research, Dr. Sikorski will oversee the strategic and
operational functions of the company's research chemistry group.
``Dr. Sikorski will play a key role in developing our medicinal chemistry strategies,'' said Russell M. Medford, M.D.,
President and Chief Executive Officer of the company. ``Jim's experience and understanding of medicinal and synthetic
organic chemistry will be critical to us as we expand our discovery capabilities to identify next generation therapeutics
for the treatment of a broad range of inflammatory diseases.''
Dr. Sikorski has nearly 20 years' experience in research, targeting specific proteins for biological activity. He has
authored or co-authored over 90 research publications as well as several reviews and book chapters. He is an inventor
or co-inventor of over 50 U.S. and foreign patents, and has been an invited speaker at numerous universities and
technical meetings in the U.S., Canada, and Europe.
Before joining AtheroGenics, Dr. Sikorski was Science Fellow of Discovery Medicinal Chemistry at Pharmacia
Discovery Research. From 1992 to 1999, Dr. Sikorski was at G. D. Searle R&D where he served most recently as
Science Fellow, Discovery Medicinal Chemistry. He received a doctorate in organic chemistry and a master of science
from Purdue University, where he worked with Nobel Laureate, Professor Herbert C. Brown. Dr. Sikorski holds a
bachelor of science degree in chemistry, with honors, from Northeast Louisiana State College..... |
